A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR) (NCT07459556) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)
China400 participantsStarted 2026-03
Plain-language summary
This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study.
* Physician decision to treat the participant with Stapokibart Injection for SAR (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.
Exclusion Criteria:
* Known history of allergic reaction to Stapokibart Injection.
* Participants currently or plan participating in any interventional clinical trial.
* Participants with hematologic malignancies.
* Women with pregnant.
* Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.
What they're measuring
1
The incidence rate of adverse reactions (ADR).
Timeframe: From enrollment to the end of treatment at 10 weeks